Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares, rose in value, with the stock price up by 4.13% to the previous day’s close as strong demand from buyers drove the stock to $0.73.
Actively observing the price movement in the last trading, the stock closed the session at $0.70, falling within a range of $0.6989 and $0.75. The value of beta (5-year monthly) was 2.186. Referring to stock’s 52-week performance, its high was $2.05, and the low was $0.42. On the whole, ADAP has fluctuated by -17.05% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With the market capitalization of Adaptimmune Therapeutics Plc ADR currently standing at about $185.54 million, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 11.17M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ADAP’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ADAP currently trading nearly -12.02% and -25.63% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 28.42, while the 7-day volatility ratio is showing 7.36% which for the 30-day chart, stands at 5.57%. Furthermore, Adaptimmune Therapeutics Plc ADR (ADAP)’s beta value is 2.22, and its average true range (ATR) is 0.05.
A comparison of Adaptimmune Therapeutics Plc ADR (ADAP) with its peers suggests the former has fared considerably weaker in the market. ADAP showed an intraday change of 4.13% in last session, and over the past year, it grew by 34.20%%.
Data on historical trading for Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) indicates that the trading volumes over the past 10 days have averaged 1.28 and over the past 3 months, they’ve averaged 1.53 million. According to company’s latest data on outstanding shares, there are 227.17 million shares outstanding.
Nearly 11.49% of Adaptimmune Therapeutics Plc ADR’s shares belong to company insiders and institutional investors own 48.82% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.56 million shares as on 2024-10-15, resulting in a short ratio of 5.0. According to the data, the short interest in Adaptimmune Therapeutics Plc ADR (ADAP) stood at 326.00 of shares outstanding as of 2024-10-15; the number of short shares registered in 2024-09-13 reached 7.0 million. The stock has fallen by -8.50% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADAP stock heading into the next quarter.
